drugset / Trial / NCT00849355
Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk
Phase 2
Unknown
44 enrolled
Asociacion Doctor Peset Para el Estudio de la Hematología
Cephalon · collabPivotal S.L. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy (and safety) of the following treatment squeme:Ciclophosphamide, Vincristine, lyposomal Doxorrubicine (Myocet) and Prednisone,combined with Rituximab in first line treatment for patients with aggresive No Hodgkin B lymphoma and cardiovascular risk
Timeline
- Start
- 2008-08
- Primary completion
- 2009-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CYCLOPHOSPHAMIDE ANHYDROUS | Small molecule | 750 mg/m2 | — |
| Subject | Doxorrubicine | Unknown | 50 mg/m2 | — |
| Subject | Prednisone | Other / unclassified | 100 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 unknown | — |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | — |
| Background | Methylprednisolone | Other / unclassified | 100 mg | — |